COVID-19非药物干预措施后育龄女性抗百日咳博德特菌抗体衰减
研究比较加拿大不列颠哥伦比亚省育龄女性2020年与2021年配对血清抗百日咳博德特菌IgG水平,2021年抗百日咳毒素和丝状血凝素IgG较2020年下降,2020年水平与2018-2019年孕早期孕妇无显著差异。
要点
- 2021年较2020年育龄女性抗百日咳毒素IgG下降(6.8 vs 8.4 IU/ml,p=0.004)。
- 2021年较2020年抗丝状血凝素IgG下降(18.8 vs 23.6 IU/ml,p<0.001)。
- 2020年育龄女性抗体水平与2018-2019年孕早期孕妇无显著差异。
核心结论
- COVID-19缓解措施放松期间应密切监测百日咳博德特菌感染。
研究设计与样本
- 配对血清研究:检测加拿大不列颠哥伦比亚省育龄女性2020年5-6月与2021年2-5月配对血样抗百日咳博德特菌IgG。
- 另检测2018年和2019年年龄匹配健康孕妇孕早期血清抗百日咳博德特菌IgG,以判断2020年早期大流行IgG是否反映孕早期水平。
- 采用t检验比较,P值0.05为界,Bonferroni校正后统计显著性设为p<0.016。
主要发现
- 不列颠哥伦比亚省2020年百日咳年发病率3/10万、2021年<1/10万,接近1990年以来最低水平。
- 2021年 vs 2020年育龄女性抗百日咳毒素IgG:6.8 IU/ml(95%CI 4.2-10.9) vs 8.4 IU/ml(95%CI 5.1-13.9),p=0.004。
- 2021年 vs 2020年抗丝状血凝素IgG:18.8 IU/ml(95%CI 10.9-32.2) vs 23.6 IU/ml(95%CI 13.2-42.1),p<0.001。
- 2021年 vs 2020年抗百日咳杆菌黏附素IgG:37.1 IU/ml(95%CI 18.1-75.9) vs 47.2 IU/ml(95%CI 24.8-89.9),p=0.092。
- 2020年育龄女性 vs 2018-2019年孕早期孕妇:抗百日咳毒素IgG 8.4 IU/ml(95%CI 5.1-13.9) vs 5.4 IU/ml(95%CI 3.8-7.7),p=0.166;抗丝状血凝素IgG 23.6 IU/ml(95%CI 13.2-42.1) vs 20.1 IU/ml(95%CI 13.4-30.2),p=0.656;抗百日咳杆菌黏附素IgG 47.2 IU/ml(95%CI 24.8-89.9) vs 17.3 IU/ml(95%CI 10.5-28.7),p=0.021。
临床怎么用
- 原文结论指出,在放松COVID-19缓解措施期间应密切监测百日咳博德特菌感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunization against Bordetella pertussis during pregnancy reduces morbidity from severe pertussis in young infants via trans-placental transfer of anti-B. pertussis Immunoglobulin G (IgG). Studies have reported a near disappearance of respiratory pathogens including B. pertussis following implementation of mitigation strategies to control Coronavirus disease 2019 (COVID-19). We explored how immunity against B. pertussis changed in women of childbearing-age through the COVID-19 pandemic. METHODS: Paired blood samples from females of childbearing-age collected at the beginning (May-June 2020) and nearly one year into the COVID-19 pandemic (February-May 2021) in British Columbia (BC), Canada were tested for anti-B. pertussis IgG levels. To ascertain whether early-pandemic IgG levels in 2020 reflected levels in pregnant women early in gestation, 1st trimester sera collected from age-matched healthy pregnant women in 2018 and 2019 were tested for anti-B. pertussis IgG. Levels were compared by t tests. P-value of 0.05 was assigned and statistical significance was set as p < 0.016 using Bonferroni correction. RESULTS: Annual provincial B. pertussis incidences per 100,000 in BC in 2020 (3/100,000) and 2021 (<1/100,000) approximated the lowest levels since 1990. In 2021 vs. 2020, anti-pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) IgG levels declined in women of childbearing-age: 6.8 IU/ml (95 %CI, 4.2-10.9) vs. 8.4 IU/ml (5.1-13.9; p = 0.004); 18.8 IU/ml (10.9-32.2) vs. 23.6 IU/ml (13.2-42.1; p < 0.001); and 37.1 IU/ml (18.1-75.9) vs. 47.2 IU/ml (24.8-89.9; p = 0.092), respectively. Although all values were slightly higher, anti-PT, FHA and PRN IgG levels in women of childbearing age did not significantly differ in 2020 compared with early-gestation pregnant women in 2018-2019, 8.4 IU/ml (95% CI, 5.1-13.9) vs. 5.4 IU/ml (95% CI, 3.8-7.7; p = 0.166), 23.6 IU/ml (95% CI, 13.2-42.1) vs. 20.1 IU/ml (95% CI, 13.4-30.2; p = 0.656), and 47.2 IU/ml (24.8-89.9) vs. 17.3 IU/ml (95% CI, 10.5-28.7; p = 0.021), respectively. DISCUSSION: B. pertussis infections should be closely monitored during the relaxing of mitigation measures for COVID-19.
引用
- Reicherz F, Golding L, Lavoie PM, et al. Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures. Vaccine. 2022. PMID: 35599039. doi:10.1016/j.vaccine.2022.04.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。